Epivara Secures $5.17M Series C Funding to Revolutionize Animal Health with iSpay/iNeuter

Epivara, formerly known as Insigna, has exciting news to share with animal welfare advocates and technology enthusiasts alike: the company has successfully raised $5,170,000 in its latest funding round.

This significant capital injection underscores the confidence that investors have in Epivara's innovative mission and transformative approach to animal care.

At the heart of this achievement is the breakthrough iSpay/iNeuter solution—a single, low-cost injection designed to offer a reliable alternative to traditional, invasive spay and neuter surgeries.

By eliminating the need for surgery, prolonged recovery periods, and the risks associated with invasive procedures, iSpay/iNeuter paves the way for a future where pet owners, animal shelters, and spay/neuter organizations can provide faster, safer, and more economical care for animals.

This new funding will be strategically directed toward enhancing research and development efforts, expanding outreach programs, and scaling production to meet global demand.

Epivara’s revolutionary approach not only promises to improve the quality of life for dogs, cats, and livestock by reducing overpopulation and behavioral challenges, but it also addresses significant animal welfare issues associated with traditional surgical procedures, especially in environments where access to anesthesia and post-operative care is limited.

With its simple administration and undeniable impact on reducing discomfort and hormone-related aggression, iSpay/iNeuter represents a shift toward compassionate innovation.

As Epivara continues to lead in this space, the raised funds will be pivotal in ensuring that more animals receive humane, efficient care, reinforcing the company’s commitment to a better future for animals and those who care for them.